Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
66 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Weber JS, Carlino MS, Khattak A, et al. · Lancet · 2024Clinical Trial, Phase II, Randomized Controlled Trial
- Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Patel SP, Othus M, Chen Y, et al. · N Engl J Med · 2023Clinical Trial, Phase II, Comparative Study
- T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.
Gainor JF, Patel MR, Weber JS, et al. · Cancer Discov · 2024Clinical Trial, Phase I
- Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.
Eggermont AM, Kicinski M, Blank CU, et al. · Eur J Cancer · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Eggermont AMM, Blank CU, Mandala M, et al. · N Engl J Med · 2018Clinical Trial, Phase III, Comparative Study
- Systemic Therapy for Melanoma: ASCO Guideline Update.
Seth R, Agarwala SS, Messersmith H, et al. · J Clin Oncol · 2023Practice Guideline, Systematic Review
- Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
Luke JJ, Ascierto PA, Khattak MA, et al. · J Clin Oncol · 2024Clinical Trial, Phase III, Randomized Controlled Trial
- Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Luke JJ, Rutkowski P, Queirolo P, et al. · Lancet · 2022Clinical Trial, Phase III, Randomized Controlled Trial
- Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma.
Luke JJ, Long GV, Robert C, et al. · Eur J Cancer · 2024Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Eggermont AMM, Blank CU, Mandalà M, et al. · Lancet Oncol · 2021Clinical Trial, Phase III, Comparative Study
- Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review.
Barron CC, Stefanova I, Cha Y, et al. · J Immunother Cancer · 2023Systematic Review
- Systemic Therapy for Melanoma: ASCO Guideline.
Seth R, Messersmith H, Kaur V, et al. · J Clin Oncol · 2020Practice Guideline, Systematic Review
- Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS, Amaria RN · Curr Treat Options Oncol · 2020Meta-Analysis, Review
- Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study.
Luke JJ, Ascierto PA, Khattak MA, et al. · Eur J Cancer · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Adjuvant therapy for cutaneous melanoma: a systematic review and network meta-analysis of new therapies.
Longo C, Pampena R, Lallas A, et al. · J Eur Acad Dermatol Venereol · 2020Systematic Review, Network Meta-Analysis
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Bührer E, Kicinski M, Mandala M, et al. · Lancet Oncol · 2024Clinical Trial, Phase III, Randomized Controlled Trial
- Preferences for Immunotherapy in Melanoma: A Systematic Review.
Livingstone A, Agarwal A, Stockler MR, et al. · Ann Surg Oncol · 2020Systematic Review
- Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Long GV, Luke JJ, Khattak MA, et al. · Lancet Oncol · 2022Randomized Controlled Trial, Multicenter Study
- Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.
Long GV, Nair N, Marbach D, et al. · Nat Med · 2025Randomized Controlled Trial, Clinical Trial, Phase I
- Primary Solitary Intracranial Malignant Melanoma: A Systematic Review of Literature.
Arai N, Kagami H, Mine Y, et al. · World Neurosurg · 2018Systematic Review
- Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
Grossmann KF, Othus M, Patel SP, et al. · Cancer Discov · 2022Clinical Trial, Phase III, Randomized Controlled Trial
- Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial.
Leachman SA, Luke JJ, Ascierto PA, et al. · JAMA Netw Open · 2026Randomized Controlled Trial, Multicenter Study
- Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis.
Toor K, Middleton MR, Chan K, et al. · BMC Cancer · 2021Comparative Study, Systematic Review
- Dabrafenib and trametinib vs anti-PD(L)1 for the adjuvant treatment of locally advanced BRAF-mutant melanoma: a systematic review and meta-analysis.
Araujo DV, Souza BL, Seibel MF, et al. · Oncologist · 2025Systematic Review, Meta-Analysis
- Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis.
Christofyllakis K, Pföhler C, Bewarder M, et al. · Front Oncol · 2020Systematic Review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.